CD117+ cells in the circulation are predictive of advanced prostate cancer

Circulating tumor cells (CTCs) are associated with cancer progression, aggressiveness and metastasis. However, the frequency and predictive value of CTCs in patients remains unknown. If circulating cells are involved in tumor aggressiveness and metastasis, then cell levels should decline upon tumor removal in localized cancer patients, but remain high in metastatic patients. Accordingly, proposed biomarkers CD117/c-kit, CD133, CXCR4/CD184, and CD34-positive cell percentages in the blood of patients undergoing radical prostatectomy for localized cancer were assessed by flow cytometry prior to intervention and 1–3 months postoperatively. Only circulating CD117+ cell percentages decreased after radical prostatectomy, increased with cancer progression and correlated with high PSA values. Notably, postoperative CD117+ levels did not decrease in patients experiencing biochemical recurrence. In a xenograft model, CD117-enriched tumors were more vascularized and aggressive. Thus, CD117 expression on CTCs promotes tumor progression and could be a biomarker for prostate cancer diagnosis, prognosis, and/or response to therapy.

[1]  T. Byzova,et al.  Platelets govern pre-metastatic tumor communication to bone , 2013, Oncogene.

[2]  J. Nesland,et al.  Synergistic effect of SCF and G-CSF on stem-like properties in prostate cancer cell lines , 2012, Tumor Biology.

[3]  T. Byzova,et al.  A novel role for platelet secretion in angiogenesis: mediating bone marrow-derived cell mobilization and homing. , 2011, Blood.

[4]  M. Tomasson,et al.  CXCR4-Mediated Bone Marrow Progenitor Cell Maintenance and Mobilization Are Modulated by c-kit Activity , 2010, Circulation research.

[5]  C. Antonescu,et al.  ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours , 2010, Nature.

[6]  E. Diamandis,et al.  Cancer biomarkers: can we turn recent failures into success? , 2010, Journal of the National Cancer Institute.

[7]  N. Agarwal,et al.  CD117 and Stro-1 identify osteosarcoma tumor-initiating cells associated with metastasis and drug resistance. , 2010, Cancer research.

[8]  E. Klein,et al.  Comparison of tumor and microenvironment secretomes in plasma and in platelets during prostate cancer growth in a xenograft model. , 2010, Neoplasia.

[9]  C. Unger,et al.  c-kit (CD117) Expression in Human Tumors and its Prognostic Value: An Immunohistochemical Analysis , 2010, Pathology & Oncology Research.

[10]  B. G. Blijenberg,et al.  Screening and prostate-cancer mortality in a randomized European study. , 2009, The New England journal of medicine.

[11]  T. Yip,et al.  Platelets actively sequester angiogenesis regulators. , 2009, Blood.

[12]  K. Leong,et al.  Generation of a prostate from a single adult stem cell , 2008, Nature.

[13]  R. Ackermann,et al.  "Cancer stem cells"-lessons from Hercules to fight the Hydra. , 2008, Urologic oncology.

[14]  R. Vessella,et al.  C-kit and its ligand stem cell factor: potential contribution to prostate cancer bone metastasis. , 2008, Neoplasia.

[15]  Michael F Clarke,et al.  The biology of cancer stem cells. , 2007, Annual review of cell and developmental biology.

[16]  L. Yujun,et al.  Cancer stem-like cells in human prostate carcinoma cells DU145: The seeds of the cell line? , 2007, Cancer biology & therapy.

[17]  Andrew J Vickers,et al.  Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Jianhua Wang,et al.  The pivotal role of CXCL12 (SDF-1)/CXCR4 axis in bone metastasis , 2007, Cancer and Metastasis Reviews.

[19]  M. Noble,et al.  Cancer stem cells. , 2006, The New England journal of medicine.

[20]  R. Autorino,et al.  Expression of proto-oncogene c-kit in high risk prostate cancer. , 2004, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[21]  D. Neal,et al.  CD133, a novel marker for human prostatic epithelial stem cells , 2004, Journal of Cell Science.

[22]  F. Balkwill.  Cancer and the chemokine network , 2004, Nature Reviews Cancer.

[23]  A. Nagler,et al.  HGF, SDF-1, and MMP-9 are involved in stress-induced human CD34+ stem cell recruitment to the liver. , 2003, The Journal of clinical investigation.

[24]  D. Bostwick,et al.  Ep-Cam levels in prostatic adenocarcinoma and prostatic intraepithelial neoplasia. , 1999, The Journal of urology.

[25]  T. Wheeler,et al.  Prognostic significance of angiogenesis in clinically localized prostate cancer (staining for Factor VIII-related antigen and CD34 Antigen) , 1997, Prostate Cancer and Prostatic Diseases.

[26]  K. Koike,et al.  Chemotactic and chemokinetic activities of stem cell factor on murine hematopoietic progenitor cells. , 1996, Blood.

[27]  C. Heldin,et al.  Activation of the human c‐kit product by ligand‐induced dimerization mediates circular actin reorganization and chemotaxis. , 1991, The EMBO journal.

[28]  W. Catalona,et al.  Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. , 1991, The New England journal of medicine.